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Introduction
Endothelial cells are essential for coagulation and fib-
rinolysis processes. Their function disturbances lead to
atherosclerosis [1] which is still the leading cause of
death in the world. 
Thrombomodulin (TM) is a marker of endothelial
cells damage. TM is a transmembrane glycoprotein
with antithrombotic properties. It inhibits thrombin
which is the main factor of thrombus formation.
Thrombin and thrombomodulin fusion on endothelial
cells surface changes thrombin function from throm-
botic to antithrombotic. It could be realized by protein
C activation. The activated form (with protein S and
phospholipid as cofactors) degrades Factor Va and
Factor VIIIa and inactivates  tissue factor plasminogen
inhibitor [2,3].
Lovastatin is one of the statins representatives. The
statins significantly reduce cholesterol level and sig-
nificantly lower morbidity and mortality related to car-
diovascular events [4,5]. They improve endothelium
function, inhibit macrophages and smooth muscles
cells proliferation and migration [6], influence hemo-
stasis and inflammation processes, stabilize athero-
sclerotic plaques [7-12].
The influence of statins on genes related to hemo-
stasis was investigated in relation to thrombomodulin,
eNOS, E-selectin, PAI-1, VCAM-1, ICAM-1,
endothelin [9,10,13-19].
All investigators are unanimous that all kinds of the
statins function are similar but differ in strength of
influence [9]. The influence of lovastatin on hemosta-
sis, especially on thrombomodulin was rarely present-
ed. The aim of our in vitro study was an assessment of
influence of increasing lovastatin concentrations on
TM gene expression in endothelial cells. The experi-
ment is a continuation of our earlier investigations
[20].
Materials and methods
Cells. Endothelial cells were derived from human umbilical veins by
enzyme method using collagenase. Cells were placed in growth
medium consisting of medium M199, fetal bovine serum (FBS) –
20% v/v and penicillin 100 IU/ml (GibcoTM) with addition 
of 50µg/ml of Endothelial Cell Growth Supplement 
(ECGS – Biomedical Technologies Inc. USA) and heparin (accord-
ing to method described in ref. 20). Cultures were placed in an incu-
bator at 37°C with 5% CO2 and a tray of water in the bottom for
humidity. After 2-4 passaging cells were used for experiment. Cells
were incubated with various concentrations of lovastatin: 0.1, 1.0 and
10.0  μmol/l. The experimental culture (with addition of lovastatin)
and control culture (without lovastatin) were incubated for 24 h.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 47, No. 1, 2009
pp. 43-45
The influence of lovastatin on thrombomodulin gene
expression in vascular endothelial cells - in vitro study
Krzysztof Góralczyk1, Krystyna Soszyñska2, Olga Haus2, Robert Bielis1, 
Danuta Roœæ1
1Depatment of Pathophysiology, 2Depatment of Clinical Genetics, 
Nicolaus Copernicus University in Toruñ, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
Abstract: Objective: Statins reduce lipids concentration in blood. The latest investigations show they also improved the
function of vascular endothelial cells (ECs). Thrombomodulin (TM) is particularly important marker of ECs activity. We
investigated the in vitro effect of lovastatin on the expression level of TM gene.Methods and results: ECs were incubated
for 24 h in culture medium including lovastatin in 3 concentrations: 0.1, 1.0, 10.0  mol/l. The mRNA level of TM increased
in correlation with rising concentrations of lovastatin to 600 % vs. control group. Conclusions: TM is essential antithrom-
botic factor in endothelial cells. Lovastatin significantly raises thrombomodulin gene expression. It is important character-
istics of this medicine, which prevents cardiovascular events.
Key words: lovastatin, thrombomodulin gene expression, endothelium 
Correspondence: K. Góralczyk, Dept. of Pathophysiology, 
Collegium Medicum Sk³odowskiej-Curie 9, 85-094 Bydgoszcz,
Poland; tel.: (+4852) 5853476, fax.: (+4852) 5853595,
e-mail: krzyg@cm.umk.pl
Gene expression. The next step was quantitative assessment of
TM gene expression. For total RNA isolation the SV Total Isola-
tion Kit was used. To synthesize cDNA 1µg of total RNA, 25 µM
random primers, 100 units SuperScript RT III, 20 units RNAsin,
1mM dNTP and RT buffer in final volume of 20 µl were used. The
reverse transcription was performed in 50°C for 50 minutes. The
final cDNA was diluted with 30 µl of H2O. RQ-PCR reaction was
carried out in 25 µl reaction mixture with 4 µl cDNA, 200 µM
dNTP, 1unit of Platinum Taq polymerase, 5mM MgCl2, 300 µM
TM primers (TM-F 5'-GATGACTGCATACTGGAGCC-3', 
TM-R 5'-CACACTCGCCGTCCACCAG-3', Gene Bank XM
009595), 300  M GAPDH primers (GAPDH-F  5'-GTGAACCAT
GAGAAGTATGAC-3', GAPDH-R 5'CACACTCGCCGTCCACC
AG-3', Gene Bank XM 006959) and 200 mM TM TaqMan probe
(FAM-cacagggtggcttcgagtgccac-TAMRA, Gene Bank XM
009595), 200 mM GAPDH TaqMan probe (FAM-
CCAACTGCTTAGCACCCCTGGCC-TAMRA, Gene Bank XM
006959). The reaction conditions were 50°C for 2 min and 95°C
for 10 min, followed by 50 cycles of 95°C for 15 s and 60°C for 60
s for annealing and extention. 
Results were assessed using ΔΔCt method which is a relative
transcript quantification using Ct value of thrombomodulin gene
(TM) comparing to reference gene GAPDH.
Lovastatin was received from Grodziskie Zak³ady Farmaceu-
tyczne "Polfa" Sp. z o.o. from Grodzisk Mazowiecki, Poland.
Ethical issues. The study obtained the approval of the local Ethics
Committee at Collegium Medicum in Bydgoszcz of Nicolaus
Copernicus University in Toruñ 31.03.2005, registry number
KB/219/2005.
Statistical analysis. Statistical analysis was performed using Sta-
tistica  for Windows (StatSoft Inc.) The results are presented as
mean ± SEM from three experiments. ANOVA test was used in the
statistical analysis. Differences were considered statistically signif-
icant when p<0.05.
Results
The increasing doses of lovastatin caused progressing
TM gene expression rise. Fig. 1 shows the results of
three experiments which are compared to controls val-
ues (culture without lovastatin) and showed as percent-
age. The lowest dose of lovastatin (0.1µmol/l) caused
increase of TM gene expression of about 120% (not sig-
nificant),  higher doses (1.0 and 10.0 µmol/l) 400% and
600%, respectively (p<0.05). Differences between the
lowest dose and higher doses ware statistically signifi-
cant (p<0.05), however differences between doses 1.0
and 10.0 µmol/l were not significant.
Discussion
The statins are group of drugs of natural and synthetic
origin. Most of studies did not show any significant
differences in the function of individual statins, they
show similar pharmacologic effect. The strength of
effectiveness depends on the statins kind [9]. Our
study was carried out using lovastatin of Polish phar-
maceutical company POLFA Grodzisk.  Most investi-
gators used pitavastatin [9,13,15] and atorvastatin [13-
15,18]. Our in vitro study shows lovastatin influence
on trombomodulin mRNA concentration in endothelial
cells which was dependent on drugs dose (Fig. 1). TM
gene expression rose progressively from 116% to
613% comparing to controls as higher doses of lovas-
tatin were added. Statistically significant differences
were obtained between the lowest dose of statin 
(0.1 µmol/l) and higher doses (1.0 and 10.0 µmol/l),
(p=0.0495). Threefold increase of TM gene expression
after 24 hours incubation of endothelial cells with
lovastatin (10.0µmol/l) comparing to control cells was
reported by van Thienen [16]. The other statins also
caused several or even more than ten times increase
[9,13-15].
The induction of the increase of gene expression of
TM which has the antithrombotic properties is an
important function of lovastatin. Statins also cause a
decrease of expression of prothrombotic factors such
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Fig. 1. The relative level of thrombo-
modulin gene expression  related to the
concentration of lovastatin.  * – denotes
statistically significant difference vs.
control.
as: E-selectin, PAI-1, VCAM-1, ICAM-1, endothelin
[13,15,17-19] and an increase of eNOS gene expres-
sion. Some investigators suggested that eNOS expres-
sion is strictly connected with TM expression [14,16].
NO is an important endothelial factor which improves
the function of endothelium by its antithrombotic and
antiatherogenic action.
Wide spectrum of the functions of statins is diffi-
cult to explain only by their influence on lipid concen-
tration. These drugs lower the cholesterol level by
inhibiting the enzyme HMG-CoA reductase and have
the influence on posttranslational proteins prenylation
by Farnezyl-PP and Geranylgeranyl-PP which are
products in cholesterol synthesis pathway. This mech-
anism is probably responsible for pleiotropic statins
effect on different type of cells [21,22].
Our previous works showed  an increased concen-
tration of TM protein on endothelial cells surface after
lovastatin exposition [20]. In the current study we
showed also lovastatin dose-dependent increase of TM
mRNA concentration which means an increased TM
gene expression and an increased production of
inhibitory protein. The increase of the expression of
this thrombin receptor means higher potential inhibito-
ry abilities of thrombomodulin as an effect of increas-
ing lovastatin doses.
Summarizing, the explicit rise of TM gene expres-
sion as an effect of lovastatin action is a real proof of
inhibitory function on blood hipercoagulability of this
drug.
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